ZAI LAB LIMITED Cost of Revenue
ZAI LAB LIMITED (ZLAB) reported Cost of Revenue of $48.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- ZAI LAB LIMITED cost of goods and services sold for the quarter ending 2026-06-30 was $48.16M, a 12.00% increase year-over-year.
- ZAI LAB LIMITED cost of goods and services sold for the quarter ending 2026-03-31 was $38.31M, a 0.36% decline year-over-year.
- ZAI LAB LIMITED cost of goods and services sold for the quarter ending 2025-12-31 was $62.30M, a 49.11% increase year-over-year.
- ZAI LAB LIMITED cost of goods and services sold for the quarter ending 2025-09-30 was $46.76M, a 27.88% increase year-over-year.
- ZAI LAB LIMITED cost of goods and services sold for fiscal 2025 was $190.52M, a 29.50% increase from fiscal 2024.
- ZAI LAB LIMITED cost of goods and services sold for fiscal 2024 was $147.12M, a 53.54% increase from fiscal 2023.
- ZAI LAB LIMITED cost of goods and services sold for fiscal 2023 was $95.82M, a 29.45% increase from fiscal 2022.
- ZAI LAB LIMITED cost of goods and services sold for fiscal 2022 was $74.02M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.16M 10-Q · filed 2026-08-06 | $86.48M 10-Q · filed 2026-08-06 | $148.78M derived: sum of 3 quarters · filed 2026-08-06 | $195.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $38.31M 10-Q · filed 2026-05-07 | $100.62M derived: sum of 2 quarters · filed 2026-05-07 | $147.38M derived: sum of 3 quarters · filed 2026-05-07 | $190.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $62.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $109.06M derived: sum of 2 quarters · filed 2026-02-26 | $152.07M derived: sum of 3 quarters · filed 2026-08-06 | $190.52M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.76M 10-Q · filed 2025-11-06 | $89.77M derived: sum of 2 quarters · filed 2026-08-06 | $128.22M 10-Q · filed 2025-11-06 | $170.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $43.00M 10-Q · filed 2026-08-06 | $81.45M 10-Q · filed 2026-08-06 | $123.24M derived: sum of 3 quarters · filed 2026-08-06 | $159.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $38.45M 10-Q · filed 2026-05-07 | $80.23M derived: sum of 2 quarters · filed 2026-05-07 | $116.80M derived: sum of 3 quarters · filed 2026-05-07 | $151.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $41.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $78.35M derived: sum of 2 quarters · filed 2026-02-26 | $113.50M derived: sum of 3 quarters · filed 2026-02-26 | $147.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $36.57M 10-Q · filed 2025-11-06 | $71.72M derived: sum of 2 quarters · filed 2025-11-06 | $105.34M 10-Q · filed 2025-11-06 | $130.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $35.15M 10-Q · filed 2025-08-07 | $68.77M 10-Q · filed 2025-08-07 | $94.00M derived: sum of 3 quarters · filed 2026-02-26 | $119.48M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $33.62M 10-Q · filed 2025-05-08 | $58.86M derived: sum of 2 quarters · filed 2026-02-26 | $84.33M derived: sum of 3 quarters · filed 2026-02-26 | $108.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $25.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $50.72M derived: sum of 2 quarters · filed 2026-02-26 | $74.48M derived: sum of 3 quarters · filed 2026-02-26 | $95.82M 10-K · filed 2026-02-26 |
| 2023-09-30 | $25.48M 10-Q · filed 2024-11-12 | $49.24M derived: sum of 2 quarters · filed 2024-11-12 | $70.58M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $23.76M 10-Q · filed 2024-08-06 | $45.10M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $74.02M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |